SciClone on the move for Friday, Dec. 22

Shares of SciClone Pharmaceuticals are among volume leaders today on Wall Street after promising news about its experimental skin cancer treatment. The company's drug Zadaxin helped increase longevity of patients with midstage skin cancer when combined with chemotherapy treatments.

Sound like SciClone is going for a positive growth in the future? we shall watch carefully in their coming 10-Q report to compare with the current 10-Q report.